论文部分内容阅读
为了评价人类免疫缺陷病毒（ＨＩＶ）疾病后期生存的老龄（＞５０岁）影响，作者分析了旧金山市ＶｅｔｅｒａｎｓＡｆｆａｌｒｓ医疗中心１９８７～１９９２年的８４６名ＨＩＶ感染病人。年龄中位数为４２岁，有１７１名（２０．２％）年龄５０岁及以上，生存测量从首次淋巴细胞检验日（ＣＤ４）细胞计数中位数，２２３个细胞／ｍｍ３）直到死亡或本研究结束。年龄在４０～４９岁的病人与年龄４０岁以下的病人比较，对其它显著的生存决定因素（ＣＤ４）百分比，ＣＤ８计数，血细胞压积，及事先已诊断为艾滋病者）的多因素比例危险调整后，在生存方面没有区别。但是，在５０～５９岁的病人（相对危险度＝１．３２，９５％可信限０．９０～１．９４）和６０岁及以上的病人中（相对危险度＝１．５６，９５％可信限０．９９～２．４６）有生存降低的趋势。然而，在美国ＨＩＶ疾病死亡率方面的老龄影响，低于总死亡率的年龄影响。因此，尽管老年ＨＩＶ感染病人的生存稍有减弱，但是这种危险不必在个体病人过于强调；对老年病人仍值得积极管理。
To assess the effect of aging (> 50 years of age) on the later stages of human immunodeficiency virus (HIV) disease, the authors analyzed 846 HIV-infected patients from 1987 to 1992 at the Veterans Affalrs Medical Center in San Francisco. The median age was 42 years, 171 (20.2%) were 50 years of age and older and the survival measured from the median CD4 count at the initial lymphocyte count (223 cells / mm3) until death or present The study is over. Patients aged 40-49 adjusted for a multi-factor risk adjusted for other significant survival determinants (CD4), CD8 count, hematocrit, and those who had previously been diagnosed with AIDS compared with those under 40 years of age After that there is no difference in survival. However, among patients aged 50-59 years (relative risk = 1.32, 95% CI 0.90-1.94) and patients 60 years of age and older (relative risk = 1.56, 95% Confidence 0.99 ~ 2.46) have a tendency to reduce their survival. However, the effect of aging on HIV disease mortality in the United States is below the age-adjusted impact of total mortality. Thus, while the survival of elderly HIV-infected patients is slightly diminished, this risk does not have to be overemphasized in individual patients; elderly patients still deserve to be actively managed.